A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
This is an open-label, single arm, dose escalation study in patients with advanced cancers.
Cancer
DRUG: CYC065
Number of patients who experience dose-limiting toxicities, cycle 1(each cycle is 21 -28 days)
Plasma concentrations, cycle 1(each cycle is 21 -28 days)|Half-life of CYC065, cycle 1(each cycle is 21 -28 days)|changes in certain protein levels in peripheral white blood cells by western blots, cycle 1(each cycle is 21 -28 days)
This is an open-label, single arm, dose escalation study in patients with advanced cancers. Treatment will be administered on an outpatient basis.